Trial Profile
Effects of canakinumab on lipid levels and inflammatory biomarkers in diabetics: a dose-ranging study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2012
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Cardiovascular disorders; Diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 24 Apr 2012 New trial record
- 27 Mar 2012 Results presented at the 61st Annual Scientific Session of the American College of Cardiology.